TTrialPathMatch Me to Trials
← Back to trials
RecruitingGlycogen Storage Disease Type IIPompe Disease

Pompe Disease Registry Protocol

Eligible age

All ages

Accepts

All genders

Locations

36 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention. * To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care. * To characterize the Pompe disease population. * To evaluate the long-term effectiveness of alglucosidase alfa.

Sponsor: Genzyme, a Sanofi Company

You may qualify if…

  • All patients with a confirmed diagnosis of Pompe disease who have signed the informed consent and authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as documented GAA enzyme deficiency from blood, skin, or muscle tissue and/or documentation of 2 GAA gene mutations.

You may not qualify if…

  • There are no exclusion criteria in this Registry

Where it's recruiting

Alabama

Birmingham

Arizona

Phoenix · Tucson

Arkansas

Little Rock

California

Irvine · Loma Linda · Los Angeles · Oakland

Colorado

Aurora

Connecticut

New Haven

District of Columbia

Washington D.C.

Florida

Coral Gables · Gainesville · Jacksonville · Tampa

Georgia

Decatur

Illinois

Aurora · Chicago

Indiana

Indianapolis

Iowa

Iowa City

Source: ClinicalTrials.gov · NCT00231400 · last updated 2026-06-23